Home » Newsletters » BioWorld Science

BioWorld Science

July 19, 2022

View Archived Issues

Fgg-impaired zebrafish present dysfibrinogenemia

PDE5A targeting enhances chemotherapy efficacy in esophageal adenocarcinoma

Amylyx sponsors research at SRI on Bax and Bak inhibitors for ALS and neurodegenerative diseases

Novel orally active NLRP3 inflammasome inhibitor alleviates DSS-induced colitis in mice

Medshine Discovery patents IRAK4 and BTK inhibitors

Inventiosbio discloses new TYK2 inhibitors

Abbisko Therapeutics describes new GTPase KRAS inhibitors

Jiangsu Tasly Diyi Pharmaceutical presents new FXR agonists

Chinese researchers synthesize new vasopressin receptor antagonists

Targeting GABA-transported GAT-3 in astrocytes reduces negative outcomes of brain injury

Organoid efficacy data leads to approval of clinical trial of rare disease drug

Researchers unveil novel markers involved in pulmonary embolism

Novel HDAC3 inhibitor shows antitumor activity in 4T1-Luc xenograft mouse model

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 10, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Skape Bio unlocks GPCR targets with de novo-designed miniproteins
BioWorld
Modulating G protein-coupled receptors (GPCRs) is one of the major challenges in biomedicine. These are flexible proteins with small, deep binding pockets. The...
Antares Therapeutics divulges new CDK2/cyclin E1 inhibitors
BioWorld Science
Antares Therapeutics Inc. has reported new CDK2/cyclin E1 inhibitors potentially useful for the treatment of cancer.
Empire Discovery Institute, Univ. of Rochester identify IRAK inhibitors
BioWorld Science
Empire Discovery Institute and the University of Rochester have discovered new interleukin-1 receptor-associated kinase 1 (IRAK-1) and/or IRAK-4 inhibitors...